From Time Magazine:

WW International Inc. stock tumbled 57% in January, the worst month for the company since it announced it was entering the weight-loss drug market. Federal Reserve’s Chair’s statement caused market slide. Eli Lilly launching a direct-to-consumer weight-loss drugs initiative caused even more market slide. Some analysts worry about waning demand for WW subscriptions.

However, the sharp reversal has some analysts spooked. Wall Street is concerned about the trends for conventional weight-loss companies like WW and the competition. They expect more clarity in March when WW releases recent trends in the wake of its new weight-loss drug offerings. Despite the concerns, WW still attracted investment, with mixed ratings and a target price that could yield a 191% return potential in the next 12 months.



Read more: WeightWatchers’ worst month ever—a stark reversal of 2023—wipes out obesity-drug gains